Testing a new oral medication for hard-to-treat blood cancer

This trial is testing olutasidenib, an oral medication taken twice daily, in a small group of Japanese patients with acute myeloid leukemia (AML) that has come back or stopped responding to previous treatment. The study focuses specifically on patients whose cancer has a particular genetic change called an IDH1 mutation. Researchers want to understand how safe and effective this medication is, and how it works in the body.

Acute myeloid leukemia that returns or becomes resistant to standard treatment is very hard to manage, and patients have limited options. This medication was designed to target the specific genetic change driving the cancer in some patients, offering a potentially new way to help people in this difficult situation.